Gastrointestinal infections, dominated by infectious diarrhea, are a major cause of inpatient morbidity, prolonged hospital stays, and public health outbreaks worldwide. For grade-A hospitals and public health systems, conventional diagnostic approaches face four core unmet needs:
Broad, complex pathogen spectrum with high mixed-infection missed diagnosis rate
Infectious diarrhea is caused by a wide range of pathogens including bacteria, viruses and parasites, with diverse pathotypes of diarrheagenic E. coli and frequent mixed infections. Traditional culture-based methods only cover a limited set of bacteria, while viral and parasitic pathogens are largely undetectable in routine workflows. This leads to high missed diagnosis rates, especially in immunocompromised inpatients, and delays targeted intervention.
Long turnaround time delays precision therapy and nosocomial infection control
Traditional bacterial culture requires 24–72 hours to deliver results, while viral and parasitic testing often relies on external reference laboratories. Clinicians commonly resort to empiric antibiotic therapy, driving unnecessary antimicrobial use. Delayed detection of nosocomial pathogens such as Clostridioides difficile also postpones infection control measures, increasing the risk of cross-transmission in wards.
High barriers to centralized molecular testing, extended sample TAT
Conventional nucleic acid testing relies on standardized PCR laboratories and certified technical personnel. Long sample transfer and batch testing cycles fail to meet the rapid diagnosis demands of emergency departments, intensive care units, infection control teams and inpatient wards.
Inefficient source tracing for foodborne outbreak public health response
Foodborne disease outbreaks require rapid pathogen identification to contain transmission. Traditional step-by-step, single-target testing is time-consuming, slowing down source tracing and emergency public health intervention.
The 26 Gastrointestinal Tract Pathogen Nucleic Acid Detection Kit, paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above clinical and public health pain points:
One-stop comprehensive 26-plex etiological profiling
A single run covers 26 targets including 16 bacterial pathogens/toxins, 6 enteric viruses and 4 parasites, covering the vast majority of clinically prevalent and public health-critical gastrointestinal pathogens. It accurately identifies both single and mixed infections, drastically reducing missed diagnosis rates and eliminating the need for sequential repeated testing.
Rapid around 80 minutes results to guide precision therapy and nosocomial control
The assay rapidly distinguishes bacterial, viral and parasitic diarrhea, enabling clinicians to shift promptly from empiric therapy to targeted treatment and reduce unnecessary antibiotic use. Fast detection of Clostridioides difficile and other nosocomial pathogens allows immediate implementation of infection control protocols, curbing in-hospital transmission and shortening length of stay for severe patients.
Low-barrier decentralized testing with shortened turnaround time
The fully automated closed system requires no specialized molecular laboratory or trained technicians, with only 1 minute of hands-on sample loading. It can be deployed directly in gastroenterology, infectious disease, emergency and infection control departments for near-patient testing, significantly cutting sample TAT and improving diagnostic efficiency.

Efficient support for public health emergency response
The broad-coverage panel enables one-time screening of most foodborne pathogens. In outbreak events, it rapidly identifies the causative agent, buying critical time for source tracing and epidemic containment, and is well suited for disease control, port of entry and grassroots public health scenarios.
Core Product Advantages
Dual-purpose panel design for severe inpatient care and public health
The 26-plex panel is tailored for severe inpatient infectious diarrhea, antibiotic-associated diarrhea and foodborne outbreak scenarios. It covers all high-prevalence clinical and priority public health gastrointestinal pathogens, meeting the needs of tertiary hospital inpatient departments, infectious disease divisions and centers for disease control.
Fully automated closed sample-to-result workflow
Powered by proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true "load-and-go" detection.
Balanced throughput for diverse clinical and public health scenarios
Compatible with the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the platform supports parallel testing of 4 samples per run with full results available in around 80 minutes. It balances speed and batch processing capacity to support routine inpatient testing, nosocomial infection screening and emergency mass screening during public health outbreaks.
Lyophilized reagents for room-temperature storage and transport
With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance and greatly reducing storage and distribution costs for facilities of all sizes and remote locations.
Zero cross-contamination closed cartridge system
Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces laboratory quality control burden, and ensures consistent, reliable test results.
Broad sample compatibility and global regulatory compliance
Validated for two mainstream clinical sample types — fresh feces and Cary-Blair preserved stool samples. All targets are CE-marked, meeting regulatory requirements for clinical diagnosis, nosocomial infection monitoring and public health screening in global markets.